SecBot SecBot

RVMD drug pipeline

$172.29
−2.3% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±4.6%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3 (completed with positive results) / pre-NDA
Time to marketNDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed

daraxonrasib Updated Jul 2

What to watch

Daraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.

Bull case
  • Phase 3 RASolute 302 results were striking: median OS 13.2 vs 6.7 months (HR 0.40), roughly doubling survival in one of the hardest-to-treat cancers (source: Dana-Farber / ASCO 2026, cancertherapyadvisor.com).
  • Pan-RAS coverage is a key differentiator, daraxonrasib inhibits multiple RAS mutations (G12X, G13X, Q61X) and wild-type RAS, unlike approved KRAS G12C-only drugs from Amgen and BMS, giving it a much larger addressable patient population (source: eureka.patsnap.com competitive analysis).
  • FDA has granted Breakthrough Therapy Designation, Orphan Drug Designation, and a Commissioner's National Priority Voucher, all signals of accelerated regulatory review and government prioritization (source: ir.revmed.com press release, June 2025).
Bear case
  • The defining binary catalyst, the Phase 3 topline readout, has already passed (April 13, 2026). The stock surged ~258% in 12 months and trades near its 52-week high of ~$193, suggesting much of the good news is already priced in.
  • No confirmed PDUFA date yet. The company stated intent to submit an NDA under the CNPV program, but there is no guarantee of acceptance, priority review, or approval timeline (source: fda.gov press release, May 1, 2026).
  • Insider selling: CEO Mark Goldsmith filed Form 144 to sell ~$1.5M of stock in June 2026. Director Sushil Patel exercised options and sold shares in the $182-$193 range under a 10b5-1 plan.
● neutral
Impact
PhasePhase 3
Time to marketAt least 2-3 years assuming successful Phase 3 readout and regulatory filing; could be accelerated if FDA allows filing based on Phase 1 data under Breakthrough Therapy Designation, but no such filing has been announced.

zoldonrasib Updated Jul 2

What to watch

Zoldonrasib is a promising next-gen KRAS G12D inhibitor with impressive Phase 1 data, but the next hard catalyst (Phase 3 readout) is years away. The stock RVMD trades near ~$187 with a consensus price target of ~$193, much of the near-term value already reflects strong daraxonrasib (RMC-6236) Phase 3 data in pancreatic cancer. Watch for regulatory filing updates given Breakthrough Therapy Designation, and enrollment updates for RASolute 305 and 309 trials. Short interest at ~6.25% of float with 4.3 days to cover adds optionality.

Bull case
  • First-in-class KRAS G12D targeted therapy, no approved drugs exist for this mutation, representing a large unmet need in pancreatic (~50% KRAS G12D), lung (~4% KRAS G12D), and colorectal cancers.
  • Phase 1 monotherapy data in NSCLC is striking: 52% ORR, 93% DCR, 11.1mo median PFS, and 73% 12-month OS (AACR 2026), comparable to approved KRAS G12C inhibitors in their indication.
  • ESMO GI 2026 combo data showed 82% ORR for zoldonrasib + chemo in 1L PDAC and 47-50% ORR for zoldonrasib + daraxonrasib in pretreated PDAC, supporting a broad label expansion strategy.
Bear case
  • Phase 3 RASolute 305 trial just began enrolling (June 2026); readout is likely 2-3+ years away with no near-term binary catalyst to drive share price.
  • Competition is emerging: Mirati/BMS' MRTX1133 (G12D inhibitor) and Amgen's AMG 193 are in earlier-stage development for the same target.
  • The stock has already rallied ~139% over 6 months and ~258% over 12 months, much of the zoldonrasib optimism may already be priced in at ~$187 with a consensus PT of ~$193 (limited 3% upside).

Other drugs in filings and trials

no drug report yet
  • RASONQUE Last: Approval · Aug 26, 2026

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Aug 26, 2026RASONQUEApproval+4.6%−1.0%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
daraxonrasibPhase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Phase 3Active not recruiting501Jun 2026